Immutep (ASX:IMM) has announced promising new data from its Phase IIb TACTI-003 trial, presented at the ESMO Immuno-Oncology Congress 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback